1	External validation of a risk score model for predicting major clinical events in adults
2	after atrial switch operation for transposition of the great arteries.
3	
4	Mathieu Albertini (1), Beatrice Santens (2), Flavia Fusco (3), Berardo Sarubbi (3), Pastora
5	Gallego (4), Maria-Jose Rodriguez-Puras (4), Katja Prokselj (5), Martijn Kauling (6), Jolien
6	Roos-Hesselink (6), Fabien Labombarda (7), Alexander Van De Bruaene (2), Werner Budts
7	(2), Laurence Iserin (1), Odilia Woudstra (8), Berto Bouma (8), Magalie Ladouceur (1)
8	
9	(1) Centre de référence des Malformations Cardiaques Congénitales Complexes, M3C.
10	Adult Congenital Heart Disease Unit, Hôpital Européen Georges Pompidou, APHP, Paris
11	Descartes University. Centre de Recherche Cardiovasculaire de Paris, INSERM U970,
12	Paris, France.
13	(2) Division of Congenital and Structural Cardiology, University Hospitals Leuven, and
14	Department of Cardiovascular Sciences, Catholic University Leuven, Leuven, Belgium.
15	(3) Adult Congenital Heart Disease Unit, AORN dei Colli - Monaldi Hospital, Naples,
16	Italy.
17	(4) Adult Congenital Heart Disease Unit, Hospital Universitario Virgin del Rocio, Sevilla,
18	Spain; European Reference Network for Rare, Low Prevalence and Complex Diseases of
19	the Heart-ERN GUARD Heart, Spain.
20	(5) Department of Cardiology, University Medical Centre Ljubljana, Slovenia. Faculty of
21	Medicine, University of Ljubljana, Slovenia.
22	(6) Department of Cardiology, Thoraxcenter, ErasmusMC, University Medical Center
23	Rotterdam, Rotterdam, the Netherlands. European Reference Network for Rare, Low
24	Prevalence and Complex Diseases of the Heart-ERN GUARD Heart, Netherlands.

1	(7)	Cardiology	Department,	CHU	de	Caen,	France.	UNICAEN,	UR	PSIR	4650,	Caen,
---	-----	------------	-------------	-----	----	-------	---------	----------	----	------	-------	-------

- 2 France.
- 3 (8) Department of Clinical and Experimental Cardiology, Heart Center, Amsterdam
- 4 Cardiovascular Sciences, Amsterdam University Medical Center, University of Amsterdam,
- 5 the Netherlands.

#### 6 **Corresponding author:**

- 7 Magalie LADOUCEUR, M.D, PhD.
- 8 Adult Congenital Heart Disease Unit
- 9 Hôpital Européen Georges Pompidou, 20 rue Leblanc, 75015 Paris
- 10 Phone: +33156093043; E-Mail : magalie.ladouceur@aphp.fr
- 11
- 12 Word Count: 4546
- 13
- 14
- 15
- 16
- 17

18

- 19
- 20
- .
- 21
- 22

- 24
- 25

#### 1 Abstract:

Background: A risk model has been proposed to provide a patient individualized estimation of risk for major clinical events (heart failure, ventricular arrhythmia, all-cause mortality) in patients with transposition of the great arteries (D-TGA) repaired by an atrial switch operation. The aim of this study was to externally validate the model.

6 Methods: A retrospective, multicentric, longitudinal cohort of 417 patients with D-TGA 7 (median age 24 years at baseline [interquartile range 18-30], 63% male) independent of the 8 model development and internal validation cohort was studied. Data on risk model predictors 9 (age >30 years, prior ventricular arrhythmia, age >1 year at atrial switch, moderate or severe 10 right ventricular dysfunction, severe tricuspid regurgitation and at least mild left ventricular 11 (LV) dysfunction) were collected from the time of baseline clinical evaluation. The 12 performance of the prediction model in predicting risk at 5 years was assessed.

**Results:** Twenty-five patients (5.9%) met the major clinical events endpoint within 5 years. Model validation showed a good discrimination between high and low 5-year risk patients (Harrell's C-index of 0.73 (95% CI 0.65–0.81)) but tended to overestimate this risk (calibration slope of 0.20 (95% CI 0.03–0.36)). We separately evaluated predictors of major clinical events in our cohort. History of heart failure and at least mildly impaired sub pulmonary LV function remained the strongest predictors of major clinical events in this population.

20 **Conclusions**: We reported the first external validation of a major clinical events risk model in 21 a large D-TGA patient population. Although a good discrimination, the model tends to 22 overestimate the absolute 5-year risk. Subpulmonary LV dysfunction appears to be a key 23 marker in the prognosis of patients with Senning and Mustard. Further optimizing risk models 24 are needed to individualize risk predictions in D-TGA patients.

1	Keywords: Risk score; Heart failure; Transposition of great arteries; Atrial switch
2	
3	
4	
5	
6	
7	
8	
9	
10	
11	
12	
13	
14	
15	
16	
17	
18	
19	
20	
21	
22	
23	
24	
25	

# 1 Clinical Perspective:

2	What is new? This is the first external validation of a risk model for major clinical events in
3	D-TGA patients after atrial switch and the largest study emphasizing the importance of
4	assessing subpulmonary left ventricle (LV) function in these patients.
5	
6	What are clinical implications?
7	- Risk model for major clinical events can be used to discriminate patients at low from
8	those at intermediate and high risk. This tool helps determine follow-up intensity, and
9	support management decisions specifically for intermediate- and high-risk patients
10	with a history of heart failure and at least mild sub pulmonary left ventricle (LV)
11	dysfunction.
12	- Sub-pulmonary LV, which can be the "forgotten chamber" in these patients with a
13	systemic right ventricle, should be carefully and regularly surveyed.
14	- Patients from the intermediate/high-risk group with history of heart failure, and
15	subpulmonary LV dysfunction have a poor prognosis and should be referred for
16	consideration of advanced therapies
17	
18	
19	
20	
21	
22	
23	
24	
25	

### **1** Non-standard Abbreviations and Acronyms:

- 2 D-TGA: Transposition of the great arteries.
- 3 AtrS: Atrial switch.
- 4 sRV: Systemic right ventricular.
- 5 CHD: Congenital heart disease.
- 6 LVOT: Left ventricle outflow tract
- 7 VSD: Ventricular septal defect

- . /

#### 1 Introduction:

2 The survival of patients with transposition of the great arteries (D-TGA) has improved 3 dramatically after introduction of the atrial switch (AtrS) procedures by Ake Senning and 4 William Mustard from the mid-1960s to the mid-1980s, when the use of the atrial switch 5 procedure became commonplace. Atrial switch procedures involve redirection of the blood 6 flow in the atria, consequently the morphological right ventricle supports the systemic 7 circulation, whereas the left ventricle (LV) supports the pulmonary circulation. Although 8 these procedures led to a significant improvement in survival during the first two decades of 9 life<sup>1</sup>, late complications are frequently encountered including systemic right ventricular (sRV) dysfunction, arrhythmias, heart failure (HF) and sudden cardiac death<sup>2 3 4</sup>. The survival at 40 10 years is estimated to be between 70 to  $80\%^{5}$  <sup>6 2</sup>. Nowadays most of patients are approaching 11 12 middle age.

Assessing the prognosis of these patients has become essential to identify patients at risk for major clinical events (HF, ventricular arrhythmia, death). This approach would allow a tailored risk prediction to support decisions for follow-up interval and therapeutic management. Patients in the category of high risk would likely benefit from referral to a quaternary center, where issues of cardiac support and heart transplantation would be discussed, considering the hardly proven effectiveness of the drug treatments in congenital heart disease (CHD) with a sRV<sup>7 8 9</sup>.

Recently, Woudstra et al provided a clinical risk model that estimates the risks of major events during the clinical course of patients with D-TGA and atrial switch. The model gave a practical risk score based on 6 criteria (age >30 years, repair at >1 year, prior ventricular arrhythmia, moderate or severe RV dysfunction, severe tricuspid regurgitation and at least mild left ventricular dysfunction) stratifying patients into low, intermediate, and high-risk groups of HF, ventricular tachycardia, and death at 5 and 10 years<sup>10</sup>. Although this prediction

1 model showed a good discriminatory ability on internal validation analysis, an external 2 validation in an independent population has not yet been performed. The aim of the current 3 study was to validate this predictive score in a large, independent, multi-center patient 4 population.

- 5
- 6 **Methods:**

7 <u>Patients:</u>

The study cohort comprised adult patients (>16 years old) with a D-TGA and atrial switch from 7 European participating centres in the MARES registry (NCT03833843) <sup>4</sup> (Hôpital Européen Georges Pompidou, Paris - Erasmus Medical Center, Rotterdam – University Hospital Leuven, Leuven - Monaldi Hospital, Naples - Hospital Virgen del Rocio, Seville -University Medical Center Ljubljana, Ljubljana - Centre Hospitalo-Universitaire de Caen, Caen). The study complies with the Declaration of Helsinki and ethical or research committee approval was obtained in each contributing centre.

Included patients were evaluated between January 2000 and December 2018. We excluded patients with missing data for calculation of the major clinical event score and those with less than 3 years of follow-up. This cohort was independent of the major clinical event score development cohort <sup>10</sup>.

19

Patients were followed up from the first hospital visit until December 2019 or the date of
primary outcome. The patients' medical records were reviewed to collect demographic
information, medical and surgical details.

The potential risk factors of clinical events in TGA after AtrS corresponded to those retained in the risk prediction score developed by Woudstra et al<sup>10</sup> and are listed in Table 1. Moreover, additional predictors selected on the basis of a literature review were assessed (in

supplemental data Table S1<sup>2,4,6,10-26</sup>). Complex TGA was defined as TGA associated with 1 2 ventricular septal defect (VSD), left ventricular outflow tract (LVOT) obstruction and/or 3 aortic coarctation. Associated pulmonary arterial hypertension was noted in the presence of 4 Eisenmenger syndrome or when pre-capillary pulmonary hypertension was invasively confirmed according to the ESC guidelines<sup>27</sup>. Atrial arrhythmia history encompassed all the 5 6 types of supraventricular arrhythmia including ectopic atrial tachycardia, atrioventricular 7 nodal reentrant tachycardia, atrioventricular reciprocating tachycardia, intra-atrial re-entry 8 tachycardia, atrial flutter, and atrial fibrillation. Holter and pacemaker/ICD monitoring, and 9 electrophysiological studies were obtained from medical records just before or at baseline. 10 Rhythm abnormalities recorded by Holter or pacemaker/ICD monitoring were classified into 11 sustained ( $\geq$  30 s) and non-sustained ( $\leq$  30 s) atrial or ventricular arrhythmias, and conduction 12 abnormalities with sinus node dysfunction and complete heart block.

13 Baseline was determined as the first visit at the adult congenital heart disease (ACHD) center 14 during the study period including clinical examination and 12-lead electrocardiography. 15 Baseline data included clinical data, brain natriuretic peptide, 12-lead electrocardiography, 16 imaging (echocardiography, cardiovascular magnetic resonance) and exercise testing 17 performed during routine follow-up. Additional predictor variables were recorded at the time 18 of, or just prior to baseline evaluation: specifically, unexplained syncope and episode of 19 sustained ( $\geq$  30 s) atrial arrhythmia. Echocardiography was considered if it was performed 20 within the year before or after the baseline visit by an experienced operator. 21 Echocardiographic sRV function was visually graded by cardiologists at each participating center as normal or mildly, moderately, or severely impaired <sup>28</sup>. Tricuspid regurgitation (TR) 22 severity was graded, according to the European guidelines, from absent/trivial to severe TR<sup>28</sup> 23 24 <sup>29</sup>. Left ventricle outflow tract obstruction (LVOT) was considered at least moderate when 25 maximum LVOT gradient > 36mmHg or Doppler maximum velocity > 3m/s. Subpulmonary

1	LV function was assessed from several parameters (visually estimated LV ejection fraction,
2	fractional area change, and MAPSE) and divided into 4 groups (normal, mildly, moderately,
3	or severely impaired) based on at least 2 parameters <sup>19</sup> . Brain natriuretic peptide (BNP) and
4	cardiopulmonary exercise testing (CPET) were considered when carried out within the 3 years
5	preceding or following the date of inclusion. Data were collected independently at
6	participating centres and data integrity was guaranteed by each participating author.
7	
8	Study outcome:
9	Primary endpoints were major clinical events defined by Woudstra et al. They included (1)
10	HF events, defined as hospitalizations for HF, heart transplantation, ventricular assist device
11	implantation, or HF as cause of death; (2) VAs, defined as symptomatic non-sustained VA,
12	sustained VA, and sudden death; and (3) all-cause mortality.
13	
14	All events occurring after patient inclusion were managed as time-dependent variables. The
15	latest follow-up data was obtained by reviewing clinical medical records or by telephone
16	contact and/or consultation with the patient.
17	
18	Statistical methods:
19	Variables are described as mean ± SD, median [interquartile range (IQR)], and numbers or
20	percentages as appropriate. Group comparisons were performed using the Student's t-test,
21	Mann–Whitney, or $\chi 2$ test where applicable. Follow-up time was calculated from the time of
22	baseline evaluation to the date of reaching the study endpoint. The Kaplan-Meier method was
23	used to estimate the incidence of reaching the study endpoint.
24	

1	Missing data: predictive variables used in the risk score model were all available. Other data
2	were no more missing than 1%, except for BNP, peak VO2, and predicted VO2, that were not
3	evaluated as predictors.
4	
5	Validation of risk prediction score of major clinical events:
6	Follow-up was censored at 5 years and the estimated 5-year risk of major events was
7	calculated for each individual patient using the following equation
8	P (major clinical events at 5-years) = 1- $0.96559^{\text{exp}(\text{prognostic index})}$
9	where prognostic index = score x $0.9841$ .
10	
11	The C-index (Harrell's) was used to measure how well the model discriminated between
12	high- intermediate- and low-risk patients (a value of 1 indicates perfect discrimination, while
13	a value of 0.5 indicates no discrimination) <sup>30, 31</sup> . Bootstrapping was used to calculate the
14	confidence intervals (CIs). The calibration slope was used to assess the degree of agreement
15	between the observed and predicted risk of major clinical events (a value close to 1 suggests
16	good overall agreement) <sup>32</sup> . Model calibration was described graphically by stratifying patients
17	into the three risk groups identified in Woudstra et al'study <sup>10</sup> .
18	
19	Association of predictors with clinical events was further assessed using Cox proportional
20	hazards method. Proportionality of hazards was confirmed in each case by assessing the
21	correlation between the scaled Schoenfeld residuals and time. All predictors with a univariate
22	value <0.05 were included into a multivariate model, after which stepwise backward selection

24 separate analysis was done in patients with a reduced anatomic LV function. P < 0.05 was

based on Akaike Information Criterion (AIC) allowed to determine the best-fit model. A

1	considered statistically significant. Analyses were performed using SAS statistical software
2	(Version 9.4, Cary, NC) and MedCalc (MedCalc Software, Mariakerke, Belgium).
3	
4	Ethics
5	This study complies with the Declaration of Helsinki. Local ethical approval was given for
6	each collaborating center with waiver of informed consent for retrospective, anonymized data
7	(NCT03833843).
8	
9	
10	Results
11	Baseline clinical characteristics:
12	Among 512 adult patients with AtrS, 417 fulfilled inclusion criteria and constituted our study
13	population (figure 1). Baseline characteristics are shown in Table 2. Compared to the Dutch
14	cohort, the European cohort was younger at baseline evaluation (median age 24 years
15	[interquartile range 18-30] vs 28 [IQR, 24-36], p<0.01), patients were more frequently
16	operated before 1 year of age (72% vs 47%, p<0.01), and sRV function was more commonly
17	impaired (49% vs 23%, p<0.01). Differences in baseline characteristics are summarized
18	in Table 2.
19	
20	Clinical outcomes:
21	The validation study cohort had a median total follow-up of 11 years (IQR 8-16; range 3-19
22	years). Seventy-three patients reached the primary endpoint (17.5%) during the study period:
23	53 patients (13%) developed HF, 10 underwent heart transplantation (2%), 21 experienced
24	ventricular arrhythmia (5%) and 15 died (4%). No patients were implanted with a ventricular
25	assist device as destination therapy. Causes of death were HF (7), sudden cardiac death (4),

1	non-cardiac death (2) and unknown (2). Median event-free survival of event-naive patients
2	surviving into adulthood was 50 years (95% CI 48-52), and median survival until death or
3	heart transplantation of adults with TGA after atrial switch was 53 years (95% CI 51-54). The
4	annual and 5-year cumulative incidence rates of major clinical events was 96.8% (95%CI
5	97.6-99.8) and 94.0% (95%CI 91.7-96.3) respectively (Figure 2A).
6	

7 According to the risk prediction model (Table 1), 298 patients had a low (71%), 92 an 8 intermediate (22%) and 27 high (6%) risk of a major clinical events. Figure 2B shows the 9 Kaplan-Meier event-free survival plotted and compared between low, intermediate, and high-10 risk group. Freedom from major clinical event survival was significantly reduced in the high-11 and intermediate-risk group compared to the low-risk group (log rank test, p<0.001). A 12 significant 95% CI overlapping was observed between the intermediate and high-risk group 13 survivals and risk of major clinical events was not significantly different between these 2 14 groups in the external validation population (Figure 2B, Figure 3). 15 Analyses were focused on the 25 patients who had major clinical events within 5 years of

follow-up (Figure 4). Baseline characteristics in those with and without a clinical event areshown in (Table 3).

18

#### 19 Major clinical event score model validation

The performance of the major clinical event score model in predicting risk at 5 years was assessed in 417 patients with 25 events. Harrell's C-index was 0.73 (95% CI 0.65–0.81). The calibration slope was 0.20 (95% CI 0.03–0.36). Figure 4 illustrates the agreement between predicted and observed 5-year cumulative proportion of major clinical event for each group of predicted risk.

## 1 Predictors of major clinical events

2	We separately performed an evaluation of predictors of major clinical events during study
3	follow-up. Predictors independently associated with major clinical events are shown in Table
4	3. Those with a significant ( $p < 0.05$ ) univariate linear relationship with the primary outcome
5	were fitted into a multivariate model. After stepwise backward selection based on AIC, the 7
6	factors included in the model were age at baseline, repair after 1 year age, history of atrial
7	arrhythmia, history of HF, NYHA >1, at least moderately sRV dysfunction and at least mild
8	subpulmonary LV dysfunction. History of HF (HR=33.19; 95%CI 9.7-113.5; p<0.01) and at
9	least mildly impaired sub pulmonary LV function (HR=2.96; 95%CI 1.31-6.70; p<0.01)
10	remained the strongest predictors of major clinical events in patients with D-TGA and atrial
11	switch.
12	
13	Patients with subpulmonary LV dysfunction had more severe sRV dysfunction compared to
14	patients without LV dysfunction (OR= 8,45; 95%CI 3,38-20,63; p<0,01). Moreover,
15	symptoms, elevated BNP, and pulmonary hypertension were also significantly more common
16	in patients with subpulmonary LV dysfunction (p<0.01) (Table 4).
17	
18	
19	Discussion:
20	This is the first study that reports on the external validation of a major clinical event risk score
21	in patients followed after atrial switch operation from a large, multicenter, independent
22	European cohort. This score, developed by Woudstra et al in 2021 <sup>10</sup> , allowed to stratify the

23 risk of composite outcomes including HF, ventricular tachycardia, sudden death, and death.

24 This information on individual absolute risk could help determine follow-up intensity, and

25 support management decisions on prevention and treatment of the prevailing complications.

From our externally validated cohort, we showed that this score discriminated well between
 high/intermediate and low-risk patients at 5 years but tended to overestimate the absolute risk
 of major events. Such as in Woudstra et al' study <sup>10</sup>, our results underscored the strong
 prognostic value of subpulmonary LV function in patients with a sRV.

5

Fewer major clinical events were observed in our cohort compared with Dutch study<sup>10</sup>. This 6 7 may be explained by significant differences between our two populations. In our cohort, most 8 patients had undergone surgery before the age of 1 year and patients were younger at study 9 entry, which could explain our lower major clinical event rate. Even though the incidence of 10 HF did not differ between the 2 populations (14% in the European registry vs 18% in the 11 Dutch study), moderate to severe sRV dysfunction was more prevalent at baseline in the 12 external validation population. This results should be cautiously interpreted because sRV 13 function was qualitatively assessed by echocardiography, which is known to have a poor interobserver reproducibility<sup>33 28</sup>. However, all echocardiography exams were performed by 14 15 experienced cardiologists specialized in ACHD, and the multicenter aspect of our study may 16 have averaged the variability in the assessment of sRV function. Moreover, sRV dysfunction 17 rate was similar to previously reported in a large cohort of 1 168 patients with AtrS operation for D-TGA<sup>11</sup>. It seems that unlike LV dysfunction in acquired heart disease, sRV dysfunction 18 19 is far from sufficient to predict the unfavorable evolution of patient with D-TGA and atrial switch. A large number of patients have sRV dysfunction for several years without an episode 20 of HF  $^{34}$ . 21

We found that the prognostic factors most associated with the occurrence of major clinical events are history of HF and subpulmonary LV dysfunction. Recently, several studies have demonstrated that adverse subpulmonary LV remodeling and systolic dysfunction were associated with worse clinical outcome in patients with a sRV <sup>19,22</sup>. Subpulmonary left

ventricular dysfunction is relatively common in patients with atrial switch and severe systemic right ventricular dysfunction; in our cohort, one third of patients with severe systemic right ventricular dysfunction have subpulmonary left ventricular dysfunction. Our results suggest that LV dysfunction is a sensitive sign of failing sRV circulation and underscore the importance of its evaluation in the routine assessment of patients with a sRV <sup>19</sup>.

The most obvious etiologies for subpulmonary LV dysfunction appear to be RV/LV interdependence and pulmonary arterial hypertension (Table 4). Precapillary pulmonary hypertension appears to be a cause of subpulmonary LV dysfunction and is a recognized complication after atrial switch, with an estimated prevalence of 6-7% <sup>35</sup>. Postcapillary pulmonary hypertension is related to atrial stiffness and dysfunction secondary to the atrial switch, tricuspid regurgitation and sRV failure<sup>36</sup>. Particular attention should be paid to the subpulmonary LV after atrial switch.

14

Our findings are complementary of those from Woudstra et al 'study<sup>10</sup>. Indeed, the risk model 15 16 allows to identify patients with high risk of major adverse events, who will require a close 17 monitoring in tertiary centers proposing therapeutic options for advanced HF like mechanical 18 circulatory support and heart transplantation. This approach should mainly concern patients 19 with intermediate or high-risk score, and even more when history of HF or at least mildly 20 impaired subpulmonary LV function are reported. The use of prognostic scores seems 21 essential to stratify the risk of events, particularly HF. Indeed, depending on the risk of HF, 22 these patients may benefit from regular monitoring, cardiac rehabilitation programs, early 23 detection and treatment of supraventricular rhythm disorders, and early HF treatment when the patient starts to be symptomatic<sup>27</sup>. Although medical therapy has failed to show preventive 24 25 efficacy on heart failure events and death in several studies, screening of high risk patients

will, maybe, allow to show some benefit in this cohort in future studies<sup>7,8</sup>. However, the 1 2 present score models evaluate a composite endpoint, and predictors may vary according to the 3 event assessed, even if several factors overlap the risk of HF and sudden cardiac death in 4 patients with a sRV. Recently, a sudden death prediction score was developed for sRV (D-5 TGA after atrial switch and congenitally corrected transposition), based on different criteria: 6 age, HF, syncope, severe right ventricular dysfunction, moderate pulmonary stenosis and QRS width<sup>4</sup>. Currently, there is no specific prognostic score for HF in this population, 7 although it is the main cause of death in adults with D-TGA and  $AtrS^{12}$ . 8

9

10 The main limitation of our study is the retrospective design, supported by the low incidence of 11 events in a rare cardiac condition. By conducting a large multicentric study, bias inherent to 12 retrospective design could be easier managed. No predictors included in the risk predictive 13 model were missing in the external validation dataset. However, some factors known to be 14 strong prognostic markers for clinical outcomes in sRV, such as BNP or peak VO2 15 measurements, were missing for more than 25% of cases and were not included in 16 multivariable analysis. Further risk prediction models should be developed by including these 17 markers. sRV function was not retained in multivariate analysis; however cardiac magnetic 18 resonance imaging measurements of sRV function might show a stronger relationship with 19 worse outcomes.

20

We reported the first external validation of a major clinical events risk model in a large D-TGA patient population. Although a good discrimination, the model tends to overestimate the 5-year risk of major clinical events. HF remains associated with poor outcome in this cardiac defect. Subpulmonary LV dysfunction appears to be a key marker in the prognosis of patients with Senning and Mustard. The development or optimizing new risk models is required,

1	particularly to predict HF and individualize the management of subgroups of patients with D-
2	TGA after AtrS.
3	
4	
5	
6	
7	
8	
9	
10	
11	
12	
13	
14	
15	
16	
17	
18	
19	
20	
21	
22	
23	

1	Acknowledgements: We thank Mrs Anissa Boubrit, a French research technician from the
2	reference center of complex congenital heart disease M3C, who helped with recording of data
3	from the Paris.
4	
5	Sources of funding: This work was supported by the Fédération Française de Cardiologie
6	and the Assistance Publique des Hôpitaux de Paris.
7	
8	Disclosure: The Authors declare that there is no conflict of interest.
9	
10	Supplemental Material:
11	Table S1
12	
13	
14	
15	
16	
17	
18	
19	
20	
21	
22	
23	
24	
25	

## 1 **Bibliographie :**

2	1. Rooshesselink J. Decline in ventricular function and clinical condition after mustard
3	repair for transposition of the great arteries (a prospective study of 22?29 years)*1. Eur Heart
4	J. 2004;25(14):1264-1270. doi:10.1016/j.ehj.2004.03.009
5	2. Cuypers JAAE, Eindhoven JA, Slager MA, et al. The natural and unnatural history of
6	the Mustard procedure: long-term outcome up to 40 years. Eur Heart J. 2014;35(25):1666-
7	1674. doi:10.1093/eurheartj/ehu102
8	3. Vejlstrup N, Sørensen K, Mattsson E, et al. Long-Term Outcome of Mustard/Senning
9	Correction for Transposition of the Great Arteries in Sweden and Denmark. Circulation.
10	2015;132(8):633-638. doi:10.1161/CIRCULATIONAHA.114.010770
11	4. Ladouceur M, Van De Bruaene A, Kauling R, et al. A new score for life-threatening
12	ventricular arrhythmias and sudden cardiac death in adults with transposition of the great
13	arteries and a systemic right ventricle. Eur Heart J. Published online June 8, 2022:ehac288.
14	doi:10.1093/eurheartj/ehac288
15	5. Couperus LE, Vliegen HW, Zandstra TE, et al. Long-term outcome after atrial
16	correction for transposition of the great arteries. Heart. 2019;105(10):790-796.
17	doi:10.1136/heartjnl-2018-313647
18	6. Dennis M, Kotchetkova I, Cordina R, Celermajer DS. Long-Term Follow-up of Adults
19	Following the Atrial Switch Operation for Transposition of the Great Arteries - A
20	Contemporary Cohort. Heart Lung Circ. 2018;27(8):1011-1017.
21	doi:10.1016/j.hlc.2017.10.008
22	7. Ladouceur M, Segura de la Cal T, Gaye B, et al. Effect of medical treatment on heart

failure incidence in patients with a systemic right ventricle. *Heart.* 2021;107(17):1384-1389.

24 doi:10.1136/heartjnl-2020-318787

25 8. Zaragoza-Macias E, Zaidi AN, Dendukuri N, Marelli A. Medical Therapy for

1	Systemic Right Ventricles: A Systematic Review (Part 1) for the 2018 AHA/ACC Guideline
2	for the Management of Adults With Congenital Heart Disease: A Report of the American
3	College of Cardiology/American Heart Association Task Force on Clinical Practice
4	Guidelines. Circulation. 2019;139(14). doi:10.1161/CIR.00000000000000604
5	9. VanderPluym CJ, Cedars A, Eghtesady P, et al. Outcomes following implantation of
6	mechanical circulatory support in adults with congenital heart disease: An analysis of the
7	Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS). J Heart
8	Lung Transplant. 2018;37(1):89-99. doi:10.1016/j.healun.2017.03.005
9	10. Woudstra OI, Zandstra TE, Vogel RF, et al. Clinical Course Long After Atrial Switch:
10	A Novel Risk Score for Major Clinical Events. J Am Heart Assoc. 2021;10(5).
11	doi:10.1161/JAHA.120.018565
12	11. Broberg CS, van Dissel A, Minnier J, et al. Long-Term Outcomes After Atrial Switch
13	Operation for Transposition of the Great Arteries. J Am Coll Cardiol. 2022;80(10):951-963.
14	doi:10.1016/j.jacc.2022.06.020
15	12. Jensen AS, Jørgensen TH, Christersson C, et al. Cause-Specific Mortality in Patients
16	During Long-Term Follow-Up After Atrial Switch for Transposition of the Great Arteries. $J$
17	Am Heart Assoc. 2022;11(14):e023921. doi:10.1161/JAHA.121.023921
18	13. Venkatesh P, Evans AT, Maw AM, et al. Predictors of Late Mortality in D-
19	Transposition of the Great Arteries After Atrial Switch Repair: Systematic Review and Meta-
20	Analysis. J Am Heart Assoc. 2019;8(21):e012932. doi:10.1161/JAHA.119.012932
21	14. Schwerzmann M, Salehian O, Harris L, et al. Ventricular arrhythmias and sudden
22	death in adults after a Mustard operation for transposition of the great arteries. Eur Heart J.
23	2009;30(15):1873-1879. doi:10.1093/eurheartj/ehp179
24	15. Wheeler M, Grigg L, Zentner D. Can we predict sudden cardiac death in long-term
25	survivors of atrial switch surgery for transposition of the great arteries? Congenit Heart Dis.

1 2014;9(4):326-332. doi:10.1111/chd.12145

2 Kammeraad JAE, van Deurzen CHM, Sreeram N, et al. Predictors of sudden cardiac 16. 3 death after Mustard or Senning repair for transposition of the great arteries. J Am Coll 4 Cardiol. 2004;44(5):1095-1102. doi:10.1016/j.jacc.2004.05.073 5 17. McCombe A, Touma F, Jackson D, et al. Sudden cardiac death in adults with 6 congenitally corrected transposition of the great arteries. Open Heart. 2016;3(2):e000407. 7 doi:10.1136/openhrt-2016-000407 8 18. Khairy P, Harris L, Landzberg MJ, et al. Sudden death and defibrillators in 9 transposition of the great arteries with intra-atrial baffles: a multicenter study. Circ Arrhythm 10 Electrophysiol. 2008;1(4):250-257. doi:10.1161/CIRCEP.108.776120 11 19. Surkova E, Segura T, Dimopoulos K, et al. Systolic dysfunction of the subpulmonary 12 left ventricle is associated with the severity of heart failure in patients with a systemic right 13 ventricle. Int J Cardiol. 2021;324:66-71. doi:10.1016/j.ijcard.2020.09.051 14 Lewis MJ, Van Dissel A, Kochav J, et al. Cardiac MRI predictors of adverse outcomes 20. 15 in adults with a systemic right ventricle. ESC Heart Fail. 2022;9(2):834-841. 16 doi:10.1002/ehf2.13745 17 21. van der Bom T, Winter MM, Groenink M, et al. Right ventricular end-diastolic 18 volume combined with peak systolic blood pressure during exercise identifies patients at risk 19 for complications in adults with a systemic right ventricle. J Am Coll Cardiol.

20 2013;62(10):926-936. doi:10.1016/j.jacc.2013.06.026

21 22. Santens B, Helsen F, Van De Bruaene A, et al. Adverse remodeling of the
22 subpulmonary left ventricle in patient with systemic right ventricle is associated with clinical

23 outcome. Eur Heart J - Cardiovasc Imaging. 2021;22(Supplement\_2):jeab090.118.

24 doi:10.1093/ehjci/jeab090.118

25 23. Babu-Narayan SV, Goktekin O, Moon JC, et al. Late gadolinium enhancement

cardiovascular magnetic resonance of the systemic right ventricle in adults with previous
 atrial redirection surgery for transposition of the great arteries. *Circulation*.
 2005;111(16):2091-2098. doi:10.1161/01.CIR.0000162463.61626.3B

4 24. Rydman R, Gatzoulis MA, Ho SY, et al. Systemic right ventricular fibrosis detected
5 by cardiovascular magnetic resonance is associated with clinical outcome, mainly new-onset
6 atrial arrhythmia, in patients after atrial redirection surgery for transposition of the great
7 arteries. *Circ Cardiovasc Imaging*. 2015;8(5):e002628.

8 doi:10.1161/CIRCIMAGING.114.002628

9 25. Geenen LW, van Grootel RWJ, Akman K, et al. Exploring the Prognostic Value of
10 Novel Markers in Adults With a Systemic Right Ventricle. *J Am Heart Assoc*.
11 2019;8(17):e013745. doi:10.1161/JAHA.119.013745

12 26. Haberger S, Hauser M, Braun SL, et al. Prognostic Value of Plasma B-Type

13 Natriuretic Peptide in the Long-Term Follow-up of Patients With Transposition of the Great

14 Arteries With Morphologic Right Systemic Ventricle After Atrial Switch Operation. Circ J

15 Off J Jpn Circ Soc. 2015;79(12):2677-2681. doi:10.1253/circj.CJ-15-0348

16 27. Backer JD, Babu-Narayan SV, Budts W, et al. The Task Force for the management of

adult congenital heart disease of the European Society of Cardiology (ESC). :83.

18 28. Li W, West C, McGhie J, et al. Consensus recommendations for echocardiography in

19 adults with congenital heart defects from the International Society of Adult Congenital Heart

20 Disease (ISACHD). Int J Cardiol. 2018;272:77-83. doi:10.1016/j.ijcard.2018.07.058

21 29. Rudski LG, Lai WW, Afilalo J, et al. Guidelines for the Echocardiographic
22 Assessment of the Right Heart in Adults: A Report from the American Society of
23 Echocardiography. J Am Soc Echocardiogr. 2010;23(7):685-713.
24 doi:10.1016/j.echo.2010.05.010

25 30. Rahman MS, Ambler G, Choodari-Oskooei B, Omar RZ. Review and evaluation of

1	performance	measures	for	survival	prediction	models	in	external	validation	settings.	BMC
---	-------------	----------	-----	----------	------------	--------	----	----------	------------	-----------	-----

- 2 *Med Res Methodol*. 2017;17(1):60. doi:10.1186/s12874-017-0336-2
- 3 31. Harrell FE, Califf RM, Pryor DB, Lee KL, Rosati RA. Evaluating the yield of medical
- 4 tests. JAMA. 1982;247(18):2543-2546.
- 5 32. Steyerberg EW. Clinical Prediction Models. Springer New York; 2009.
  6 doi:10.1007/978-0-387-77244-8
- 7 33. Chaix MA, Dore A, Marcotte F, et al. Variability in the Echocardiographic Evaluation
- 8 of the Systemic Right Ventricle. *Can J Cardiol.* 2019;35(2):178-184.
  9 doi:10.1016/j.cjca.2018.11.021
- 10 34. Andrade L, Carazo M, Wu F, Kim Y, Wilson W. Mechanisms for heart failure in
- systemic right ventricle. *Heart Fail Rev.* 2020;25(4):599-607. doi:10.1007/s10741-01909902-1
- 13 35. Ebenroth ES, Hurwitz RA, Cordes TM. Late onset of pulmonary hypertension after
  14 successful mustard surgery for d-transposition of the great arteries. *Am J Cardiol.*15 2000;85(1):127-130. doi:10.1016/S0002-9149(99)00625-6
- 16 36. Chaix M, Dore A, Mercier L, et al. Late Onset Postcapillary Pulmonary Hypertension
- 17 in Patients With Transposition of the Great Arteries and Mustard or Senning Baffles. J Am
- 18 Heart Assoc. 2017;6(10):e006481. doi:10.1161/JAHA.117.006481
- 19
- 20
- 21
- 22
- 23
- 24
- 25

# **<u>TABLE:</u>**

	2
Criteria	Scoțe
	points
Age > 30 years	1  4
Repair at $> 1$ year	1,5
Prior ventricular arrhythmia	1 5
$\geq$ Moderate RV dysfunction	1
Severe tricuspid regurgitation	1,56
$\geq$ Mild LV dysfunction	1,5

**Table 1,** Major clinical event score developed by Woudstra et al<sup>10</sup>. A risk score between 0-2

8 corresponded to the low-risk group with a predicted 5-year risk <5%, a score between 2.5-3.5

- 9 to the intermediate-risk group with a predicted risk of 5-20%, and a score between 4-7.5 to the
- 10 high-risk group with a predicted risk >20%.

- 1.5

- \_\_\_

Characteristics	Validation cohort	Dutch cohort	P Value
	(N= 417)	(N=167)	
Age	24 (18-29)	28 (24–36)	<0.01
Aged>30 y	102 (24%)	74 (44%)	<0.01
Gender, male	261 (63%)	104 (62%)	0.86
Senning procedure	212 (51%)	66 (40%)	0.12
Complex TGA	112 (27%)	51 (31%)	0.60
Repair > 1 year	115 (28%)	89 (53%)	<0.01
Subsequent interventions after	108 (26%)	32 (19%)	0.41
atrial switch surgery			
Supraventricular tachycardia	140 (36%)	58 (35%)	0.88
Complete pregnancy	73 (18%)	NA	NA
Pulmonary arterial hypertension	26 (6%)	NA	NA
Prior heart failure	18 (4%)	8 (5%)	0.83
Prior ventricular tachycardia	38 (9%)	13 (8%)	0.91
NYHA I	304 (73%)	128 (77%)	0.39
NYHA ≥ II	112 (27%)	39 (25%)	0.80
Moderate or severe impairment	205 (49%)	38 (23%)	<0.01
of RV function			
Severe tricuspid regurgitation	22 (5%)	12 (8%)	0.73
Mild or greater impairment of	35 (8%)	8 (5%)	0.77
LV function			
Severe mitral regurgitation	1 (0,2%)	NA	NA
Moderate pulmonary stenosis	55 (13%)	NA	NA
Cardiac treatment	155 (37%)	NA	NA
Beta-blockers	74 (18%)	28 (17%)	0.91

Diuretics	31 (7%)	14 (8%)	0.91
ACEi/ARA 2	107 (26%)	45 (27%)	0.90
Pacemaker	93 (22%)	41 (25%)	0.70
ICD for primary prevention	29 (7%)	5 (3%)	0.74

1 **Table 2. Baseline Characteristics and comparison with Dutch cohort.** ACEi,

2 Angiotensin-converting enzyme inhibitor; ARA 2, Angiotensin II receptor antagonist; ICD,

3 implantable cardioverter-defibrillator; LV, left ventricle; NYHA, New-York Heart

4 Association; TGA, Transposition of the Great Arteries.

5	
6	
7	
8	
9	
10	
11	
12	
13	
14	
15	
16	
17	
18	
19	
20	
21	
22	

Clinical characteristic	Composite end- point ( <i>n</i> = 73)	No composite endpoint	Hazard ratio (95% CI)	<i>P</i> -value
		( <i>n</i> = 344)		
Age	27 (20-32)	23 (18-29)	1.09 (1.05 - 1.12)	<0.01
Gender (male)	46 (63%)	215 (62%)	1.00 (0.62 - 1.61)	0.96
Aged >30y	25 (34%)	77 (22%)	2.58 (1.57 – 4.23)	<0.01
Aged >1 y at AtrS	33 (45%)	82 (24%)	2.41 (1.52 - 3.82)	<0.01
Mustard procedure	44 (60%)	161 (46%)	1.22 (0.86 - 1.96)	0.40
Complex anatomy	32 (44%)	80 (23%)	0.92 (0.49 - 1.72)	0.81
Symptoms (NYHA>1)	30 (41%)	83 (24%)	2.71 (1.68 – 4.34)	<0.01
Prior HF	56 (77%)	16 (5%)	30.51 (17.40 - 53.30)	<0.01
Prior VA	12 (16%)	26 (8%)	1.76 0.94 - 3.26)	0.07
Prior atrial arrhythmia	46 (63%)	94 (27%)	3.52 (2.18 - 5.66)	<0.01
РАН	13 (18%)	13 (4%)	3.43 (1.88 - 6.26)	<0.01
Pacemaker	31 (42%)	62 (18%)	2.94 (1.84 - 4.68)	<0.01
Moderate or greater RV dysfunction	53 (73%)	198 (56%)	1.76 (1.05 – 2.95)	<0.03
Severe tricuspid regurgitation	11 (15%)	11 (3%)	3.47 (1.83 - 6.61)	<0.01
LVOT obstruction	16 (22%)	39 (11%)	1.71 (0.98 – 2.97)	0.06
Mild or greater LV dysfunction	18 (25%)	17 (5%)	4.88 (2.85 - 8.33)	<0.001
Moderate or severe mitral regurgitation	3 (4)	2 (0.6%)	4.78 (1.15 – 19.86)	0.03
BNP (pg/mL)	371 (223-1007)	130 (68-236)	1.00 (1.00 - 1.00)	<0.01
Peak VO2 (ml/mn/kg)	19.2 (15.7-22.5)	23.6 (17.5-27.5)	0.92 (0.88 - 0.97)	<0.01
VO2 predicted (%)	47.0 (35.0-53.0)	61.0 47.7-68.3)	0.97 (0.94 - 0.99)	0.01

1	Table 3. Baseline characteristics of patients with and without major clinical events. AtrS,
2	atrial switch; HF, Heart Failure; LV, left ventricle; NYHA, New-York Heart Association;
3	PAH, Pulmonary Arterial Hypertension.
4	
5	
6	
7	
8	
9	
10	
11	
12	
13	
14	
15	
16	
17	
18	
19	
20	

Variable	Patient with Mild or greater impairment of LV function (N = 35)	Patient without impairment of LV function (N= 382)	Odds Ratio (IC 95%)	P Value
Normal RV function	0	46 (12%)	0,21 (0,01-1,32)	0,210
Mild impairment of sRV function	12 (34%)	154 (40%)	0,77 (0,34-1,67)	0,589
Moderate impairment of sRV function	11 (31%)	160 (42%)	0,64 (0,27-1,40)	0,282
Severe impairment of sRV function	12 (34%)	22 (6%)	8,45 (3,38-20,63)	<0,01
РАН	10 (29%)	16 (4%)	9,05 (3,32-23,90)	<0,01
NYHA 2-4	18 (51%)	94 (25%)	3,23 (1,50-6,98)	<0,01
BNP (N=265)	1584 (659,25- 7278)	139,8 (78-259)	1,00 (1,00-1,00)	0,012

1 Table 4. Comparison in univariate analysis of patients with and without subpulmonary

2 left ventricular dysfunction. BNP, Brain Natriuretic Peptide; LV, left ventricle; NYHA,

3 New-York Heart Association; PAH, Pulmonary Arterial Hypertension; sRV: systemic Right

- 4 Ventricle.

#### **FIGURES :**





- 2 Figure 2A. Kaplan–Meier curve showing event-free survival of the whole external
- 3 validation population. Shaded area corresponds to 95% confidence interval.
- 4



2 Figure 2B. Kaplan–Meier curve showing event-free survival of the external validation

3 cohort by risk category. Shaded areas correspond to 95% confidence intervals.

4

5

6



2 Figure 3. Kaplan–Meier curves showing event-free survival by risk category at 5 years.







2 Figure 4. Comparison of observed and predicted risk by risk group of the major clinical

3 events proposed risk model. Vertical bars represent model-based predicted (orange) and

4 observed (blue) probability of events at 5 years. The low-risk group corresponds to a

5 predicted 5-year risk <5%, the intermediate-risk group to a predicted risk of 5 - 20%,

6 and the high-risk group to a predicted risk >20%.

- 7
- 8